Characteristics of patients
. | sUCBT platform . | Haplo-Cord platform . | P . |
---|---|---|---|
No. of patients | 135 | 72 | |
Age, y | .004 | ||
Median | 33 | 35 | |
Range | 16-53 | 16-64 | |
Age group, y, no. (%) | .1 | ||
16-20 | 26 (19) | 7 (10) | |
21-30 | 37 (27) | 17 (24) | |
31-40 | 38 (28) | 20 (28) | |
>40 | 34 (25) | 28 (39) | |
Sex, no. (%) | 1 | ||
Male | 78 (58) | 42 (58) | |
Female | 56 (42) | 30 (42) | |
Weight, kg | .3 | ||
Median | 70 | 72 | |
Range | 37-105 | 42-111 | |
Diagnosis, no. (%) | 1 | ||
AML | 74 (55) | 45 (63) | |
ALL | 61 (45) | 27 (37) | |
Disease stage at transplant, no. (%) | .1 | ||
First complete remission | 73 (54) | 44 (61) | |
Second or beyond complete remission | 43 (32) | 14 (20) | |
Relapsed or refractory | 19 (14)* | 14 (20)† | |
CMV serologic status before transplantation, no. (%) | .4 | ||
Positive | 108 (80) | 55 (86) | |
Negative | 27 (20) | 9 (14) | |
Time of follow-up of surviving patients, mo | .4 | ||
Median | 66 | 51 | |
Range | 9-127 | 15-116 |
. | sUCBT platform . | Haplo-Cord platform . | P . |
---|---|---|---|
No. of patients | 135 | 72 | |
Age, y | .004 | ||
Median | 33 | 35 | |
Range | 16-53 | 16-64 | |
Age group, y, no. (%) | .1 | ||
16-20 | 26 (19) | 7 (10) | |
21-30 | 37 (27) | 17 (24) | |
31-40 | 38 (28) | 20 (28) | |
>40 | 34 (25) | 28 (39) | |
Sex, no. (%) | 1 | ||
Male | 78 (58) | 42 (58) | |
Female | 56 (42) | 30 (42) | |
Weight, kg | .3 | ||
Median | 70 | 72 | |
Range | 37-105 | 42-111 | |
Diagnosis, no. (%) | 1 | ||
AML | 74 (55) | 45 (63) | |
ALL | 61 (45) | 27 (37) | |
Disease stage at transplant, no. (%) | .1 | ||
First complete remission | 73 (54) | 44 (61) | |
Second or beyond complete remission | 43 (32) | 14 (20) | |
Relapsed or refractory | 19 (14)* | 14 (20)† | |
CMV serologic status before transplantation, no. (%) | .4 | ||
Positive | 108 (80) | 55 (86) | |
Negative | 27 (20) | 9 (14) | |
Time of follow-up of surviving patients, mo | .4 | ||
Median | 66 | 51 | |
Range | 9-127 | 15-116 |